• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The World Market for Biomarkers (Cardiac Markers [cTn, HscTn, Acute CK-MB/BNP, Others], Tumor Markers [PSA, CEA, CA 125, AFP, PSA Rapid, Others], Coagulation Markers [PT/INR, D-dimer], Infectious Disease Markers [by Disease], Immunological Disease Markers [Autoimmune/Allergy], Neurological Markers, C-Reactive Protein and Other Markers)

$5,000.00 – $10,000.00

Clear
SKU: 19-044 Categories: Diagnostics Market Research, Immunoassays, Infectious Disease, Oncology & Hematology Market Reports Tags: C-Reactive Protein (CRP) Market, Cancer Biomarker Market, Cardiovascular Disease Biomarker Market, Clinical Diagnostic Biomarker Market, Immunological Disease Biomarker Market, Infectious Disease Biomarker Market, Neurological Disease Biomarker Market, Research Biomarker Market Pages: 266
  • Description
  • Table of Contents
  • Latest reports

Description

Biomarkers are biological or biochemical molecules, genetic changes, or other characteristics that can be measured; they indicate or predict a condition, risk, or likely biological response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications. The World Market for Biomarkers estimates the world markets for biomarkers and biomarker tests from 2014 to 2024, with 2019 as the base year, providing global biomarker market forecasts for the total biomarker market, the market by application (clinical diagnostic biomarker market, research biomarker market), and the market by geographical distribution:

  • Total Global Biomarker Market by Application, 2014 – 2024, in $Millions (Clinical Diagnostic, Research, Total)
  • Biomarker Market Segments by Application, 2014, 2019, 2024, by Share (%) (Clinical Diagnostic, Research)
  • Total Global Biomarker Market by Region 2014 – 2024, in $Millions (North America, European Union, Japan, China, India, ROW, Total)
  • Global Market Segments by Region, 2014, 2019, 2024, by Share (%) (North America, European Union, Japan, China, India, ROW)

 

Clinical Diagnostic Biomarker Market by Disease

In 2019, growth in the total global market for clinical diagnostic markers has been strong, with strong expansion expected to continue. The report discusses how this growth will be fueled by an aging population that is more susceptible to disease, the increasing number of targeted therapies being developed and introduced, and the large and growing clinical diagnostic test market. Further, analysis in the report of key segments, such as the infectious disease and cancer segments, shows that growth will occur at different rates. The report provides the following data on segments of the clinical diagnostic biomarker market by disease:

  • Total Global Clinical Diagnostic Biomarker Market, 2014 – 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other, Total)
  • Clinical Diagnostic Biomarker Market Segments, 2014, 2019, 2024, by Share (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)

 

Cancer Biomarker Market

Cancer immunoassays (tumor markers) detect proteins in the blood, urine, or other body fluids such as sputum, breast nipple aspirate, and semen. The presence of these proteins, or their relative levels, may indicate an abnormal process in the body, such as cancer, and can provide further information if cancer is diagnosed. Doctors use tumor marker tests at various stages in patient care: for diagnosis, treatment monitoring and disease recurrence. The report provides the following cancer biomarker market data:

  • Total Global Clinical Diagnostic Cancer Biomarker Market, 2014 – 2024, in $Millions (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Total)
  • Clinical Diagnostic Cancer Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
  • Total Global Clinical Diagnostic Cancer Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Histology/Cytology: Immunohistochemistry, In Situ Hybridization; Immunoassays – Tumor Markers: PSA, CEA, CA 125, AFP, Others, Flow Cytometry; Rapid Tests: Fecal Occult Blood, PSA, NMP22, Others; Molecular Assays; Total)

 

Infectious Disease Biomarker Market

The largest disease segment at this time is infectious diseases. This market includes tests to detect antigens or nucleic acid (DNA or RNA) sequences from microbes, and also markers of the body’s response to the infection, such as antibodies produced against a specific pathogen that has infected a person. These are important biomarkers to determine if a person is, or has been, infected. These biomarkers can also sometimes be used to demonstrate the efficacy of treatment. For bacterial infections, antibiotic resistance genes are also important biomarkers to predict which antibiotics are not likely to be effective for treatment of a bacterial infection. The report provides the following infectious disease biomarker market data:

  • Total Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 – 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
  • Growth of Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 – 2024, in $Millions (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
  • Clinical Diagnostic Infectious Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
  • Total Global Clinical Diagnostic Infectious Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Laboratory Immunoassays [Hepatitis; HIV; STDs including chlamydia, gonorrhea and syphilis; TORCH; Respiratory; Sepsis including sepsis markers, C. difficile, MRSA, other AMR/HAI tests; Parasitology; Mycology; Others including EBV, Chagas, dengue, malaria, Lyme disease, others], Rapid Immunoassays [Influenza; HIV; Malaria; Hepatitis; STDs including chlamydia and syphilis; C. difficile; E. coli; Strep A; H. pylori; Others including rapid tests for TB, Dengue, Chagas, vaginitis, Group B Strep and others], Molecular Assays [HAIs; HIV; Hepatitis; Chlamydia/Gonorrhea (CT/NG); HPV; Respiratory; Mycobacteria/TB; Others], Total)

 

Cardiovascular Disease Biomarker Market

Cardiac biomarkers are substances that are released into the bloodstream when the heart is damaged or stressed. As discussed in the report, cardiovascular disease includes all diseases or disorder of the heart and the vascular system of the body. Many different biomarkers have been identified to help physicians diagnose disease, identify individuals at increased risk of disease, and to monitor certain conditions. The World Market for Biomarkers provides the following information on the global diagnostic market for cardiovascular disease biomarkers:

  • Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2014 – 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
  • Clinical Diagnostic Cardiovascular Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cardiac Markers, Cholesterol/Lipids, Coagulation)
  • Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Cardiac Markers [Acute Condition Cardiac Markers: CK-MB, myoglobin, brain natriuretic peptide (BNP); cTn; HscTn; Other cardiac markers: proBNP, hsCRP, homocysteine, others], Cholesterol/Lipids, Coagulation [PT/INR-lab, D-dimer, Molecular (Thrombophilia SNPs), POC], Total)

 

Immunological Disease Biomarker Market

There are many different diseases that involve an abnormal immune response, as discussed in the report. Two immunological disease categories for which diagnostic testing is commonly performed are autoimmune disease and allergy. More than 80 different autoimmune related diseases have been identified. In addition, individuals can develop an allergic response to a wide array of allergens. As a result, these diagnostic markets include a wide range of different biomarkers that can be tested. The report provides the following information on the sales of biomarkers related to immunological disease:

  • Total Global Clinical Diagnostic Immunological Disease Biomarker Market, 2014 – 2024, in $Millions (Autoimmune Disease, Allergy, Total)
  • Clinical Diagnostic Immunological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Autoimmune Disease, Allergy)

 

Neurological Disease Biomarker Market

Neurological diseases are those that affect the central nervous system (brain and spinal cord) and the peripheral nervous system. This group encompasses many age-related diseases such as dementia, neurodegenerative diseases, inherited neurodevelopmental disorders, as well as autoimmune diseases such as multiple sclerosis, diabetic neuropathy, stroke, and many others. Because they are systemic, distinct, complex and generally not as widespread as the illnesses discussed elsewhere in this report, biomarker development in this area has been slower. However, the aging of the population and rapid increase of severe and costly diseases such as Alzheimer’s disease has made this area a priority for a rising number of research groups. As such, it is a fast growing biomarker segment of which the report notes total global sales:

  • Total Global Clinical Diagnostic Neurological Disease Biomarker Market, 2014 – 2024, in $Millions (Autoimmune Disease, Allergy, Total)
  • Clinical Diagnostic Neurological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Alzheimer’s Disease, Other Neurological Disorders)

 

Other Diseases

The “other” segment includes many different types of biomarkers used in diagnostic applications such as bone diseases, renal disease, transplantation, other endocrine diseases, and other varied disease indications. As discussed in the report, a broad definition of biomarkers is used has been used in this report. Biomarkers in this report include molecules or other characteristics that can be measured, and are indicators of a health, risk of disease, disease or other condition, prognosis, response to therapy, or other biological effect. This definition includes biomarkers that are used in drug development as surrogates, markers of drug safety, or other applications. Traditionally, biomarkers have been discussed and evaluated as single molecules or characteristics, and many tests are available for individual biomarkers. The World Market for Biomarkers provides the following information on the sales of biomarkers related to the following segments: general clinical chemistry, fertility/pregnancy, thyroid, diabetes/Hb1Ac, chromosome analysis & inherited disease, and other:

  • Total Global Clinical Diagnostic Other Biomarker Market, 2014 – 2024, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other, Total)
  • Clinical Diagnostic Other Biomarker Market Segments, 2014, 2019, 2024, by Share (%)(General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)

 

C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is an important biomarker for several diseases. Due to the high and rising interest in CRP tests, a breakout of estimated sales is provided:

  • Total Global CRP Biomarker Market, 2014 – 2024, in $Millions

 

Biomarker Market Drivers and Restraints

For this report, the market for biomarkers focuses on applications of biomarkers. This includes both research and diagnostic applications of biomarkers. The potential market for biomarkers being evaluated as potential drug targets is not included in this market analysis, as that therapeutic market would be determined by the potential market for new therapies targeting the biomarker drug target.

The report examines biomarker market drivers and restraints. As in other markets, a variety of drivers and restraints exert influences to varying degrees. Some of these drivers and restraints operate at a macro level, affecting the entire industry, while others mainly affect certain segments, companies, geographies, or other select situations. The market for a biomarker that is developed and commercialized for diagnostic applications is driven by the market and need for diagnostic assays that detect that biomarker.

 

Key Technologies Used to Identify & Analyze Biomarkers

Many different technologies have been developed and are used in biomarker discovery, and also for detection and analysis of known biomarkers. These include traditional technologies, some of which have been used for decades. In addition, many new technologies developed for other applications are now being applied in this field. These include mass spectrometry and next generation DNA sequencing. Many tests performed using newer technologies are currently being done primarily as laboratory developed tests (LDTs) or by organizations performing clinical tests for pharmaceutical companies developing new drugs; however, some companies plan to eventually develop IVD test kits based on their laboratory assays. Selected examples of companies using these various technologies are discussed in this report, including key players in the market:

  • Selected Companies Using Immunoassays for Detection and Analysis of Biomarkers, 2019
  • Selected Companies with Immunohistochemistry Tests for Detection of Biomarkers, 2019
  • Selected Companies Using In Situ Hybridization for Detection and Analysis of Biomarkers, 2019
  • Selected Companies Using PCR or Other Nucleic Acid Amplification-Based Technologies for Biomarker Assays, 2019
  • Selected Companies Analyzing Gene Signatures, 2019
  • Selected Companies Using Microarrays to Detect and Analyze Biomarkers, 2019
  • Selected Diagnostics Companies and Clinical Laboratories with Sequencing-Based Biomarkers, 2019
  • Selected Companies Using Mass Spectrometry, 2019

 

Competition in the Market

The World Market for Biomarkers includes profiles of companies active in the discovery and/or commercialization of biomarkers. This includes companies commercializing in vitro diagnostic tests for detection and analysis of biomarkers, selected diagnostic companies commercializing diagnostic tests in their own CLIA certified laboratories for detection and analysis of biomarkers, and selected other players. The report’s focus is on companies with commercialized products and/or very advanced development programs. The diagnostics market is a highly competitive market, and there are many additional diagnostic companies that offer tests based on biomarkers discussed in this report. Companies profiled in the report range from large, multinational companies to smaller companies in or entering this market, including the following:

  • 20/20 GeneSystems, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Act Genomics Co., Ltd.
  • Adaptive Biotechnologies Corp.
  • Admera Health
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies, Inc.
  • ALPCO
  • Ambry Genetics Corp.
  • Athena Diagnostics, Inc. /Quest
  • Banyan Biomarkers, Inc.
  • Beckman Coulter, Inc./Danaher Corp.
  • Becton, Dickinson and Company
  • BioFire Diagnostics, LLC/BioMerieux
  • Biohit Oyj
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Cancer Genetics, Inc.
  • Caris Life Sciences
  • Cepheid/Danaher Corp.
  • Curetis AG
  • Exact Sciences Corp.
  • Foundation Medicine, Inc.
  • Fujirebio, Inc.
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics
  • NeoGenomics
  • Ortho-Clinical Diagnostics
  • Qiagen N.V.
  • Roche
  • Siemens Healthineers
  • Sysmex Corp.
  • Thermo Fisher Scientific, Inc.
  • Ventana Medical Systems, Inc./Roche
  • Zeus Scientific, Inc.

Table of Contents

Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Summary

  • Exhibit 1-1: Total Global Biomarker Market, 2014 ñ 2024, in $Millions
  • Exhibit 1-2: Growth of Total Global Biomarker Market, 2014 ñ 2024, in $Millions

Chapter 2: Introduction
Overview

  • What Are Biomarkers?
  • Why Biomarkers Are Important
  • Biomarker Validation
    • Exhibit 2-1: FDA-Qualified Biomarkers, 2019

Chapter 3: Key Technologies Used to Identify & Analyze Biomarkers
Overview
Immunoassays

  • Key Players
    • Exhibit 3-1: Selected Companies Using Immunoassays for Detection and Analysis of Biomarkers, 2019

Immunohistochemistry (IHC)

  • Key Players
    • Exhibit 3-2: Selected Companies with Immunohistochemistry Tests for Detection of Biomarkers, 2019

Flow Cytometry

  • Key Players

In Situ Hybridization

  • Key Players
    • Exhibit 3-3: Selected Companies Using In Situ Hybridization for Detection and Analysis of Biomarkers, 2019

Nucleic Acid Amplification Technologies

  • Key Players
    • Exhibit 3-4: Selected Companies Using PCR or Other Nucleic Acid Amplification-Based Technologies for Biomarker Assays, 2019

Pharmacogenomics

  • Exhibit 3-5: Pharmacogenomic Biomarkers in Drug Labeling, 2019

Gene Signatures

  • Key Players
    • Exhibit 3-6: Selected Companies Analyzing Gene Signatures, 2019

Microarrays

  • Key Players
  • Protein Microarrays
    • Exhibit 3-7: Selected Companies Using Microarrays to Detect and Analyze Biomarkers, 2019
  • DNA Microarrays
  • Chromosomal Microarrays
  • Tissue Microarrays

Sequencing Technologies

  • Key Players
    • Exhibit 3-8: Selected Diagnostics Companies and Clinical Laboratories with Sequencing-Based Biomarkers, 2019
  • Sanger Sequencing
  • Early Next Generation Sequencing Technologies
  • Sequencing by Synthesis (SBS)
  • Supported Oligonucleotide Ligation and Detection (SOLiD)
  • Ion Torrent Sequencing

Mass Spectrometry

  • Research and Clinical Applications of Mass Spectrometry
  • Key Players
    • Exhibit 3-9: Selected Companies Using Mass Spectrometry, 2019

Non-Invasive Prenatal Testing
Liquid Biopsies ñ Circulating Tumor Cells and Circulating Tumor DNA (Cell Free DNA)
Digital Pathology and Image Cytometry
Information Technology

Chapter 4: Cancer Biomarkers
Overview

    • Exhibit 4-1: Widely Used Tumor Markers, 2019

Assessing Risk of Cancer

  • Key Players
    • Exhibit 4-2: Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer and Companies Marketing These Biomarkers, 2019

Cancer Screening

  • Key Players
    • Exhibit 4-3: Selected Biomarkers and Biomarker Panels for Cancer Screening and Companies Marketing These Biomarkers, 2019

Diagnosis and Monitoring of Cancer

  • Key Players
    • Exhibit 4-4: Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer and Companies Marketing These Biomarkers, 2019

Predicting Prognosis

  • Key Players
    Personalized Medicine/Precision Testing

    • Key Players
      • Exhibit 4-5: Selected FDA Cleared/Approved Companion Diagnostic Tests and Companies Marketing These Biomarkers, 2019

Chapter 5: Cardiovascular Disease Biomarkers
Overview
Acute Myocardial Infarction and Acute Coronary Syndrome Biomarkers

  • Key Players
    Heart Failure Biomarkers

    • Exhibit 5-1: Selected Biomarkers and Biomarker Panels for Cardiovascular Disease and Companies Marketing These Biomarkers, 2019

Lipid Disorder Biomarkers

  • Key Players
    • Exhibit 5-2: Selected Lipid Biomarkers and Companies Marketing These Biomarkers, 2019

Chapter 6: Immunological Disease Biomarkers
Overview

  • Key Players

Autoimmune Disease Biomarkers
Inflammation/Inflammatory Disease Biomarkers
Other Immune-Related Disease Biomarkers

  • Exhibit 6-1: Selected Biomarkers for Immunological Disorders and Companies Marketing These Biomarkers, 2019

Chapter 7: Infectious Disease Biomarkers
Overview
Infectious Disease Biomarkers

  • Key Players
    • Exhibit 7-1: Selected Biomarkers for Infectious Disease and Companies Marketing These Biomarkers, 2019

Antibiotic Resistance Biomarkers

  • Key Players
    • Exhibit 7-2: Selected Biomarkers and Other Tests for Antibiotic Resistance and Companies Marketing These Biomarkers, 2019

Sepsis Biomarkers

  • Key Players
    • Exhibit 7-3: Selected Biomarkers for Sepsis and Companies Marketing These Biomarkers, 2019

Chapter 8: Neurological Disease Biomarkers
Overview

  • Key Players

Alzheimerís Disease Biomarkers
Other Neurological Disorder Biomarkers

  • Exhibit 8-1: Selected Biomarkers for Neurological Disorders and Companies Marketing These Biomarkers, 2019

Chapter 9: Global Biomarker Market Forecasts
Overview
Total Biomarker Market
Biomarker Market by Application

  • Clinical Diagnostic Biomarker Market
  • Research Biomarker Market
    • Exhibit 9-1: Total Global Biomarker Market by Application, 2014 ñ 2024, in $Millions (Clinical Diagnostic, Research, Total)
  • Exhibit 9-2: Growth of Global Biomarker Market by Application, 2014 ñ 2024, in $Millions (Clinical Diagnostic, Research)
  • Exhibit 9-3: Biomarker Market Segments by Application, 2014, 2019, 2024, by Share (%) (Clinical Diagnostic, Research)

Biomarker Market Geographical Distribution

  • Exhibit 9-4: Total Global Biomarker Market by Region 2014 ñ 2024, in $Millions (North America, European Union, Japan, China, India, ROW, Total)
  • Exhibit 9-5: Growth of Global Biomarker Market by Region, 2014 ñ 2024, in $Millions (North America, European Union, Japan, China, India, ROW)
  • Exhibit 9-6: Global Market Segments by Region, 2014, 2019, 2024, by Share (%) (North America, European Union, Japan, China, India, ROW)

Clinical Diagnostic Biomarker Market by Disease

  • Exhibit 9-7: Total Global Clinical Diagnostic Biomarker Market, 2014 ñ 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other, Total)
  • Exhibit 9-8: Growth of Total Global Clinical Diagnostic Biomarker Market, 2014 ñ 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)
  • Exhibit 9-9: Clinical Diagnostic Biomarker Market Segments, 2014, 2019, 2024, by Share (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)
  • Cancer Biomarker Market
    • Exhibit 9-10: Total Global Clinical Diagnostic Cancer Biomarker Market, 2014 ñ 2024, in $Millions (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Total)
    • Exhibit 9-11: Growth of Global Clinical Diagnostic Cancer Biomarker Market, 2014 ñ 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
    • Exhibit 9-12: Clinical Diagnostic Cancer Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
    • Exhibit 9-13: Total Global Clinical Diagnostic Cancer Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Histology/Cytology: Immunohistochemistry, In Situ Hybridization; Immunoassays – Tumor Markers: PSA, CEA, CA 125, AFP, Others, Flow Cytometry; Rapid Tests: Fecal Occult Blood, PSA, NMP22, Others; Molecular Assays; Total)
  • Cardiovascular Disease Biomarker Market
    • Exhibit 9-14: Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2014 ñ 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
    • Exhibit 9-15: Growth of Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2014 ñ 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation)
    • Exhibit 9-16: Clinical Diagnostic Cardiovascular Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cardiac Markers, Cholesterol/Lipids, Coagulation)
    • Exhibit 9-17: Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Cardiac Markers [Acute Condition Cardiac Markers: CK-MB, myoglobin, brain natriuretic peptide (BNP); cTn; HscTn; Other cardiac markers: proBNP, hsCRP, homocysteine, others], Cholesterol/Lipids, Coagulation [PT/INR-lab, D-dimer, Molecular (Thrombophilia SNPs), POC], Total)
  • Immunological Disease Biomarker Market
    • Exhibit 9-18: Total Global Clinical Diagnostic Immunological Disease Biomarker Market, 2014 ñ 2024, in $Millions (Autoimmune Disease, Allergy, Total)
    • Exhibit 9-19: Growth of Global Clinical Diagnostic Immunological Disease Biomarker Market, 2014 ñ 2024, in $Millions (Autoimmune Disease, Allergy)
    • Exhibit 9-20: Clinical Diagnostic Immunological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Autoimmune Disease, Allergy)
  • Infectious Disease Biomarker Market
    • Exhibit 9-21: Total Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 ñ 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
    • Exhibit 9-22: Growth of Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 ñ 2024, in $Millions (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
    • Exhibit 9-23: Clinical Diagnostic Immunological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
    • Exhibit 9-24: Total Global Clinical Diagnostic Infectious Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Laboratory Immunoassays [Hepatitis; HIV; STDs including chlamydia, gonorrhea and syphilis; TORCH; Respiratory; Sepsis including sepsis markers, C. difficile, MRSA, other AMR/HAI tests; Parasitology; Mycology; Others including EBV, Chagas, dengue, malaria, Lyme disease, others], Rapid Immunoassays [Influenza; HIV; Malaria; Hepatitis; STDs including chlamydia and syphilis; C. difficile; E. coli; Strep A; H. pylori; Others including rapid tests for TB, Dengue, Chagas, vaginitis, Group B Strep and others], Molecular Assays [HAIs; HIV; Hepatitis; Chlamydia/Gonorrhea (CT/NG); HPV; Respiratory; Mycobacteria/TB; Others], Total)
  • Neurological Disease Biomarker Market
    • Exhibit 9-25: Total Global Clinical Diagnostic Neurological Disease Biomarker Market, 2014 ñ 2024, in $Millions (Autoimmune Disease, Allergy, Total)
    • Exhibit 9-26: Growth of Global Clinical Diagnostic Neurological Disease Biomarker Market, 2014 ñ 2024, in $Millions (Alzheimer’s Disease, Other Neurological Disorders)
    • Exhibit 9-27: Clinical Diagnostic Neurological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Alzheimer’s Disease, Other Neurological Disorders)
  • Other Biomarker Markets
    • Exhibit 9-28: Total Global Clinical Diagnostic Other Biomarker Market, 2014 ñ 2024, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other, Total)
    • Exhibit 9-29: Growth of Global Clinical Diagnostic Other Biomarker Market, 2014 ñ 2024, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)
    • Exhibit 9-30: Clinical Diagnostic Other Biomarker Market Segments, 2014, 2019, 2024, by Share (%)(General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)
  • C-Reactive Protein (CRP)
    • Exhibit 9-31: Total Global CRP Biomarker Market, 2014 ñ 2024, in $Millions
    • Exhibit 9-32: Growth of Global CRP Biomarker Market, 2014 ñ 2024, in $Millions

     

Chapter 10: Biomarker Market Analysis
Overview
Market Drivers and Restraints

  • Market Drivers
  • Market Restraints

Chapter 11: Company Profiles

    • Exhibit 11-1: Selected Players in the Global Biomarker Market, 2019

20/20 GeneSystems, Inc.
Abacus Diagnostica Oy
Abbott Laboratories
Act Genomics Co., Ltd.
Adaptive Biotechnologies Corp.
Admera Health
Agena Bioscience Inc.
Agendia NV
Agilent Technologies, Inc.
ALPCO
Ambry Genetics Corp.
Athena Diagnostics, Inc. /Quest
Banyan Biomarkers, Inc.
Beckman Coulter, Inc./Danaher Corp.
Becton, Dickinson and Company
BioFire Diagnostics, LLC/BioMerieux
Biohit Oyj
bioMÈrieux SA
Bio-Rad Laboratories, Inc.
Cancer Genetics, Inc.
Caris Life Sciences
Cepheid/Danaher Corp.
Curetis AG
Exact Sciences Corp.
Foundation Medicine, Inc.
Fujirebio, Inc.
Genomic Health, Inc.
Hologic, Inc.
Illumina, Inc.
Myriad Genetics
NeoGenomics
Ortho-Clinical Diagnostics
Qiagen N.V.
Roche
Siemens Healthineers
Sysmex Corp.
Thermo Fisher Scientific, Inc.
Ventana Medical Systems, Inc./Roche
Zeus Scientific, Inc.

    Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition
    May 13, 2025
    In Vitro Diagnostic (IVD) Trends and Market Update, 2025
    April 7, 2025
    In Vitro Diagnostics Business Outlook, 2025 (6 Issues)
    April 3, 2025
    Molecular Diagnostics Quarterly Datastream, 2025
    April 2, 2025

Related products

  • Placeholder image

    U.S. Market for Over-the-Counter Diagnostics: Product Sales and Consumer Survey, The

    $4,995.00 – $9,990.00
  • Placeholder image

    Diagnostics for Emerging Infectious Disease Threats Volume III: Bacterial Disease

    $1,995.00 – $3,990.00
  • Placeholder image

    Molecular Diagnostics for Pharmacogenetic Testing: Testing volume, cost per test, and market potential

    $995.00 – $1,990.00
  • Placeholder image

    Biophotonics – A Strategic Assessment of Photonics Technologies for Biomedical Applications

    $2,995.00 – $5,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Molecular Testing Markets for Infectious Diseases (Sepsis, Respiratory Diseases,...The Worldwide Market for In Vitro Diagnostic Tests: 12th Edition
Scroll to top